 |
Most type 2 diabetes patients ‘unaware of heart risks’Seventy-four per cent of patients in the UAE don’t believe that type 2 diabetes is associated with increased cardiovascular risk, said the Emirates Diabetes Society in its findings of a Type 2 Diabetes Patient survey. The su More… |
 |
Boehringer Ingelheim unveils 15 new medicinesBoehringer Ingelheim, a family-owned pharmaceutical company, recently unveiled 15 new medicines could potentially be approved by 2025 in immunology, CNS, oncology, respiratory and cardio metabolic diseases. The company pres More… |
 |
Boehringer Ingelheim adds Merial to animal health unitBoehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies, has announced that Merial, a leading animal health company, has become part of the Boehringer Ingelheim organisation. “We have united More… |
 |
Boehringer Ingelheim names Mideast headBoehringer Ingelheim, a leading German pharmaceutical company, has appointed Enrique Manzoni as its country managing director for the region. Manzoni will lead the overall operations in the Middle East, Turkey and Africa region ba More… |
|
Boehringer Ingelheim names Mideast headBoehringer Ingelheim, a leading German pharmaceutical company, has appointed Enrique Manzoni as its country managing director for the region. Manzoni will lead the overall operations in the Middle East, Turkey and Africa region ba More… |
 |
Boehringer Ingelheim opens new office in KuwaitBoehringer Ingelheim, one of the world’s leading pharmaceutical companies, recently opened its new office in Kuwait. The opening ceremony was held in YIACO Medical Company’s (YIACO) headquarters, in Salmiya, and where More… |
 |
Saudi German Hospital opens new stroke unitSaudi German Hospital (SGH) Riyadh, one of the largest private hospitals with a capacity of 300 beds, recently its first stroke unit in partnership with Boehringer Ingelheim, a top pharmaceutical company. The stroke unit, which is More… |
 |
Boehringer Ingelheim introduces new treatment options for cancerBoehringer Ingelheim, a leading pharmaceutical company, recently presented its new treatment for epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) at an educational session held in Dubai, UAE. More… |
 |
Boehringer launches stroke management academyGermany-based Boehringer Ingelheim, a leading pharmaceutical company, has launched an academy to establish comprehensive stroke management protocol in the region. The first of its kind introduced in the region, the Stroke Academy More… |
 |
Hikma acquires assets of US pharma groupHikma Pharmaceuticals, a leading medical group in the region, has signed an agreement with Boehringer Ingelheim Group of Companies to acquire the assets of Bedford Laboratories for $300 million. Hikma is a fast growing multination More… |
